Key intracellular pathway and epigenetic targets and potential therapies
Category . | Target . | Potential agents . |
---|---|---|
BTK inhibitors | BTK | Ibrutinib |
BTK | Acalabrutinib | |
BTK | ONO/GS-4059 | |
BTK | BGB-3111 | |
BTK | CC-292 | |
PI3K inhibitors | PI3Kδ | Idelalisib |
PI3K δ and γ | Duvelisib | |
PI3K δ and α | Copanlisib | |
PI3Kδ | TGR1202 | |
Syk inhibitors | Syk | Fostamatinib* |
Syk | Entospletinib | |
BCL2 inhibitors | BCL2 | Venetoclax |
MDM2 inhibitors | MDM2 | Idasanutlin |
MDM2 | DS-3032b | |
Epigenetic modifiers | EZH2 | Tazemetostat |
EZH2 | CPI-1205 | |
EZH2 | GSK2816126 |
Category . | Target . | Potential agents . |
---|---|---|
BTK inhibitors | BTK | Ibrutinib |
BTK | Acalabrutinib | |
BTK | ONO/GS-4059 | |
BTK | BGB-3111 | |
BTK | CC-292 | |
PI3K inhibitors | PI3Kδ | Idelalisib |
PI3K δ and γ | Duvelisib | |
PI3K δ and α | Copanlisib | |
PI3Kδ | TGR1202 | |
Syk inhibitors | Syk | Fostamatinib* |
Syk | Entospletinib | |
BCL2 inhibitors | BCL2 | Venetoclax |
MDM2 inhibitors | MDM2 | Idasanutlin |
MDM2 | DS-3032b | |
Epigenetic modifiers | EZH2 | Tazemetostat |
EZH2 | CPI-1205 | |
EZH2 | GSK2816126 |
No longer in development in NHL.